Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Instagram Outage Disrupts Thousands of U.S. Users 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
CHESTER, N.J., June 12, 2017 -- Hillstream BioPharma Inc. (Hillstream), a biopharmaceutical company focused on developing targeted, safer and more effective cancer therapeutics, will present at the 2017 Marcum MicroCap Conference on June 16 at the Grand Hyatt in New York City. Randy Milby, Chief Executive Officer, will present an update on the company and answer questions at 11:00 am ET.
Hillstream BioPharma Inc. is dedicated to developing cancer therapeutics with greater safety and efficacy to help patients with high unmet medical needs. Hillstream’s lead drug, HBP-407, is a novel proprietary formulation of bortezomib, with an improved side effect profile with the potential for reduced peripheral neuropathy, activity against bortezomib-resistant multiple myeloma and a highly targeted effect with the potential for an increased dose to expand the first approved proteasome inhibitor into solid tumors.
Randy Milby, Hillstream’s CEO, said, “Side effects, such as peripheral neuropathy, and drug resistance are two serious problems in cancer patient care. We believe HBP-407 can offer a safer, more effective targeted therapeutic in an orphan population with a high unmet need.”
The Marcum MicroCap Conference (www.marcummicrocap.com) is a nationally recognized forum for publicly traded companies with less than $500 million in market capitalization to network with fund managers and high net worth investors who focus on small cap equities. More than 2000 investors and other participants from every segment of the microcap marketplace attend each year, including venture and lower middle-market private equity investors, institutional investors, directors, investment bankers, and buy- and sell-side analysts, as well as senior executive teams from presenting companies and service providers to the microcap marketplace.
The conference is presented by Marcum LLP, a top national accounting and advisory firm registered with the Public Company Accounting Oversight Board (PCAOB). Marcum's Assurance Division provides the most up-to-date service and guidance on SEC accounting and reporting issues. For more information, visit www.marcumllp.com.
About Hillstream BioPharma Inc.
Hillstream BioPharma Inc. (Hillstream) is a biopharmaceutical company focused on developing cancer therapeutics with greater safety and efficacy to help patients with high unmet medical needs. Hillstream’s lead drug, HBP-407, is a novel proprietary formulation of bortezomib, with an improved side effect profile with the potential for reduced peripheral neuropathy, activity against bortezomib-resistant multiple myeloma and a highly targeted effect with the potential for increased dose to expand the first approved proteasome inhibitor into solid tumors. Hillstream will initially utilize the faster and more de-risked FDA’s 505(b)(2) NDA regulatory pathway for approval of HBP-407. Our goal is to develop pharmaceutical products which play an important role in helping patients lead longer and healthier lives. Please also see www.hillstreambio.com.
Contact: Randy Milby [email protected] www.hillstreambio.com
